Tenaya Therapeutics, Inc. announced changes to its Research leadership team, including new appointments to the company?s Scientific Advisory Board (SAB). Kathy Ivey, Ph.D., Vice President of Gene Therapy Research, will be promoted to Senior Vice President, Research, with responsibility for all Tenaya?s non-clinical research and discovery work. Timothy Hoey, Ph.D., who has served as Tenaya?s Chief Scientific Officer since 2017, will step down from his role.

Dr. Hoey will remain with the Company in an advisory capacity, including joining Tenaya?s Scientific Advisory Board (SAB) and serving as a consultant to Tenaya?s Science & Technology Committee. In addition, Barry J. Byrne, M.D., Ph.D., Professor and Associate Chair of Pediatrics, Molecular Genetics & Microbiology Director, Powell Gene Therapy Center, University of Florida School of Medicine, has also been appointed to Tenaya?s SAB. Separately, Tenaya also announced that Jin-Long Chen, Ph.D., is stepping down from the company?s Board of Directors following more than seven years of service to focus on other commitments, including his role as Managing Partner of TCG Labs Soleil.